In May of 2024, the Department of Justice (DOJ) placed a Notice of Proposed Rulemaking in the Federal Register6 that would transfer marijuana from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA. Although the current Administration of the federal government has not carried forth with the proposal, the Drug Policy Subcommittee of the American Society for Pharmacology and Experimental Therapeutics (ASPET) would like to make the membership aware of the ramifications of such a rule change and especially for those with preclinical and clinical research programs involving cannabis.
Does it matter what scientific journal you publish your latest findings in? Many journals associated with non-profit scientific societies have been around for decades (some for over a century) and represent the gold standard in their fields. However, since 2000 there has been a massive proliferation of for-profit journals that have made it challenging for society journals to maintain their pipeline of submissions.
Its “Awards Season” at ASPET. Learn more about why ASPET Executive Officer, Dave Jackson, encourages members to nominate peers and colleagues (or themselves) for the ASPET Fellows, Scientific Achievement Awards, and Division-Sponsored Awards.
Ashim Malhotra Appointed as Vice President at California Northstate University, ASPET Welcomes New Members
Honoring ASPET members who have passed.
Why Your Voice Matters: The Power of Advocacy Through In-District Meetings. You do not have to work on Capitol Hill to shape public policy. Some of the most influential conversations happen far from Washington, in local offices, community spaces, research institutions, and spaces where Members of Congress meet with constituents like you.
A showcase of early-career scientists—what drives them and why pharmacology is important to them.
The Publications Committee thanks these new editorial board members and all ASPET board members for their service and dedication to the Society’s journals.
